DexCom, Inc. (NASDAQ:DXCM) Stock Holdings Lowered by Dowling & Yahnke LLC

Dowling & Yahnke LLC reduced its holdings in DexCom, Inc. (NASDAQ:DXCMGet Rating) by 9.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,718 shares of the medical device company’s stock after selling 1,277 shares during the quarter. Dowling & Yahnke LLC’s holdings in DexCom were worth $6,507,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Rise Advisors LLC purchased a new position in DexCom during the fourth quarter valued at approximately $26,000. Riverview Trust Co purchased a new position in DexCom during the first quarter valued at approximately $25,000. Equitec Proprietary Markets LLC purchased a new position in DexCom during the fourth quarter valued at approximately $29,000. American National Bank purchased a new position in DexCom during the fourth quarter valued at approximately $37,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new position in DexCom during the fourth quarter valued at approximately $37,000. 93.26% of the stock is currently owned by institutional investors.

Insider Transactions at DexCom

In other news, Director Steven Robert Pacelli sold 1,000 shares of the company’s stock in a transaction dated Monday, July 25th. The shares were sold at an average price of $83.07, for a total value of $83,070.00. Following the sale, the director now owns 138,700 shares of the company’s stock, valued at approximately $11,521,809. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director Steven Robert Pacelli sold 1,000 shares of the company’s stock in a transaction dated Monday, July 25th. The shares were sold at an average price of $83.07, for a total value of $83,070.00. Following the sale, the director now owns 138,700 shares of the company’s stock, valued at approximately $11,521,809. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Jereme M. Sylvain sold 600 shares of the company’s stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $301.57, for a total transaction of $180,942.00. Following the completion of the sale, the chief financial officer now directly owns 17,408 shares in the company, valued at approximately $5,249,730.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 3,627 shares of company stock valued at $676,977. 0.41% of the stock is owned by insiders.

DexCom Trading Up 3.7 %

Shares of DXCM stock opened at $85.80 on Thursday. DexCom, Inc. has a 52-week low of $66.89 and a 52-week high of $164.86. The stock has a market cap of $33.68 billion, a price-to-earnings ratio of 165.80, a P/E/G ratio of 3.27 and a beta of 1.03. The company has a debt-to-equity ratio of 0.90, a quick ratio of 4.79 and a current ratio of 5.27. The firm has a fifty day moving average of $84.90 and a 200-day moving average of $99.83.

DexCom (NASDAQ:DXCMGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The medical device company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.04). DexCom had a net margin of 8.23% and a return on equity of 12.42%. The business had revenue of $628.80 million during the quarter, compared to analyst estimates of $623.97 million. During the same quarter in the prior year, the company posted $0.08 EPS. The company’s quarterly revenue was up 24.5% compared to the same quarter last year. On average, equities research analysts forecast that DexCom, Inc. will post 0.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

DXCM has been the topic of a number of research analyst reports. Raymond James lowered their price objective on shares of DexCom from $134.50 to $121.50 in a research report on Friday, April 29th. SVB Leerink decreased their target price on shares of DexCom from $141.25 to $125.00 in a research report on Friday, April 29th. Canaccord Genuity Group decreased their target price on shares of DexCom from $131.25 to $125.00 in a research report on Friday, April 29th. BTIG Research decreased their target price on shares of DexCom from $135.00 to $105.00 and set a “buy” rating for the company in a research report on Friday, June 24th. Finally, StockNews.com assumed coverage on shares of DexCom in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Two analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.00.

About DexCom

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Stories

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMGet Rating).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.